HomeCompareNVDS vs MRK

NVDS vs MRK: Dividend Comparison 2026

NVDS yields 13.42% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVDS wins by $17.6K in total portfolio value
10 years
NVDS
NVDS
● Live price
13.42%
Share price
$29.61
Annual div
$3.97
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.4K
Annual income
$3,089.16
Full NVDS calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — NVDS vs MRK

📍 NVDS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVDSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVDS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVDS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVDS
Annual income on $10K today (after 15% tax)
$1,140.93/yr
After 10yr DRIP, annual income (after tax)
$2,625.79/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, NVDS beats the other by $1,818.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVDS + MRK for your $10,000?

NVDS: 50%MRK: 50%
100% MRK50/50100% NVDS
Portfolio after 10yr
$39.6K
Annual income
$2,019.73/yr
Blended yield
5.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NVDS
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVDS buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVDSMRK
Forward yield13.42%3.25%
Annual dividend / share$3.97$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$48.4K$30.7K
Annual income after 10y$3,089.16$950.29
Total dividends collected$21.8K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NVDS vs MRK ($10,000, DRIP)

YearNVDS PortfolioNVDS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,042$1,342.27$11,192$351.54+$850.00NVDS
2$14,396$1,510.66$12,524$392.70+$1.9KNVDS
3$17,091$1,687.77$14,015$438.65+$3.1KNVDS
4$20,160$1,872.69$15,682$489.96+$4.5KNVDS
5$23,636$2,064.46$17,547$547.23+$6.1KNVDS
6$27,553$2,262.03$19,632$611.16+$7.9KNVDS
7$31,946$2,464.35$21,963$682.53+$10.0KNVDS
8$36,852$2,670.35$24,571$762.18+$12.3KNVDS
9$42,311$2,878.96$27,486$851.08+$14.8KNVDS
10$48,362$3,089.16$30,745$950.29+$17.6KNVDS

NVDS vs MRK: Complete Analysis 2026

NVDSStock

Under normal market circumstances, the adviser will maintain at least 80% exposure to financial instruments that provide one and a quarter times inverse leveraged exposure to the daily performance of NVDA. The fund is an actively-managed ETF that seeks to achieve on a daily basis, before fees and expenses, -125% performance of NVDA for a single day, not for any other period, by entering into one or more swap agreements on NVDA. It is non-diversified.

Full NVDS Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this NVDS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVDS vs SCHDNVDS vs JEPINVDS vs ONVDS vs KONVDS vs MAINNVDS vs JNJNVDS vs ABBVNVDS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.